Search Results

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47.

Ethris GmbH announced preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda, in healthy participants.

Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA therapeutics and vaccines, announced it will be a founding member of a new global organization called Alliance for mRNA Medicines.

Ethris GmbH announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized Non-Immunogenic mRNA platform and encodes for type III interferon that plays a vital role in early antiviral response.

Ethris GmbH and Heqet Therapeutics announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction and in heart failure.

Ethris GmbH announced that it has received approval from the United Kingdom Medicines and Healthcare products Regulatory Agency to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.

Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, and DIOSynVax, a Cambridge UK based clinical stage biotech spinout specialized in the development of multi-valent vaccine antigen payloads (VAPs), announced today the publication of preclinical proof of concept results for each of their platform technologies in Nature Biomedical Engineering.